Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. (SGHT) is the issuer for a Rule 144 notice filed for the account of former officer Jeremy B. Hayden covering planned sales of common stock. The notice lists 12,219 shares of common stock to be sold, associated with restricted stock vesting on August 31, 2026, held in an account at Fidelity Brokerage Services LLC.
The filing also lists several prior sales of Sight Sciences common stock by Jeremy Hayden during the past three months, each with its own date, share amount, and aggregate sale price. The notice is signed on September 4, 2026, by Jessica Spraker as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jeremy Hayden.
Sight Sciences, Inc. (SGHT) is the issuer for a planned sale of common stock reported under Rule 144 for the account of former officer Jeremy B. Hayden. A brokerage account at Fidelity Brokerage Services LLC filed notice to sell up to 13,253 shares of SGHT common stock, with an indicated value of $109,974.72. The securities relate to restricted stock vesting on 08/31/2026, received from the issuer as compensation. The filer notes that the sale includes an amount necessary to cover a tax obligation arising from settlement of a vested equity award.
In the prior three months, Jeremy Hayden reported several open-market sales of SGHT common stock, including 12,733 shares on 07/06/2026 for $70,132.10 and 48,000 shares on 08/14/2026 for $395,880.00, along with additional transactions on 08/11/2026, 08/12/2026, 08/13/2026, and 08/17/2026.
Sight Sciences, Inc. (SGHT) reported that its Chief Legal Officer, the reporting person in this Form 4, received an equity compensation award. The officer was granted 181,818 restricted stock units (RSUs) of common stock for no cash consideration, increasing the officer’s directly held common stock-related position to 181,818 shares on an as-converted basis.
The RSUs were granted under Sight Sciences’ 2021 Incentive Award PlanAugust 10, 2027 and continuing through August 10, 2030, subject to the officer’s continued service with Sight Sciences on each vesting date. Each RSU represents a contingent right to receive one share of Sight Sciences common stock.
Sight Sciences, Inc. (SGHT) reported that Kashif Rashid, serving as Chief Legal Officer, filed an initial Form 3 as an officer of the company. The filing lists no reportable transactions or equity holdings and includes a Power of Attorney authorizing Form 3-related actions.
Sight Sciences, trading under symbol SGHT, has a filing stating that shareholder Jeremy Hayden plans to sell up to 12,014 shares of common stock through Fidelity Brokerage Services LLC on or after August 17, 2026 on NASDAQ, with an indicated aggregate market value of $97,841.48.
The disclosure also lists prior common stock sales by Hayden during July and August 2026, and notes that some shares derive from restricted stock vesting granted as compensation on January 1, 2024 and June 30, 2026.
Jeremy Hayden filed a Form 144 indicating an intent to sell 48,000 shares of common stock of SGHT through Fidelity Brokerage Services LLC on August 14, 2026, in connection with a stock option exercise on NASDAQ. The planned sale has an indicated aggregate market value of $395,878.84.
Over the prior three months, Hayden reported sales of SGHT common stock totaling 52,453 shares for aggregate proceeds of $389,080.31 across four transactions on July 6, August 11, 12, and 13, 2026.
SGHT-related securities holder filed a notice of intent to sell 2,500 shares of common stock, held at Fidelity Brokerage Services, with an indicated value of $20,762.50 and a planned sale date of August 13, 2026 on NASDAQ. The filing also notes that these 2,500 shares arise from restricted stock vesting on June 30, 2026 as compensation, and lists prior common stock sales over the past three months by Jeremy Hayden on July 6, 2026, August 11, 2026, and August 12, 2026.
Jeremy Hayden filed a notice relating to planned sales of SGHT common stock through Fidelity Brokerage Services LLC. The filing lists prior equity awards, including restricted stock vesting of 6,737 shares on January 15, 2024, 4,598 shares on March 28, 2024, and 4,967 shares scheduled for January 15, 2026, all as compensation from the issuer. It also reports sales during the past three months: 12,733 common shares on July 6, 2026 for $70,132.10 and 20,918 common shares on August 11, 2026 for $165,878.62.
SGHT insider Jeremy Hayden filed to sell up to 20,918 shares of common stock through Fidelity Brokerage Services, with an estimated aggregate market value of $165,878.62, to be sold on or after August 11, 2026 on NASDAQ.
The shares relate to prior and scheduled restricted stock vesting events treated as compensation. In addition, Hayden reported having sold 12,733 shares of common stock for $70,132.10 on July 6, 2026 under Form 144’s “securities sold during the past 3 months” section.
Sight Sciences, Inc. appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary effective August 10, 2026, succeeding Jeremy Hayden, who will step down on that date and stay through August 31, 2026 to assist with transition. Rashid brings extensive legal and corporate development experience from prior roles at Nevro Corp., Atara Biotherapeutics, St. Jude Medical and General Electric’s healthcare business.
Under his employment agreement, Rashid will receive an initial annual base salary of $450,000 and will be eligible for an annual cash bonus targeted at 50% of base salary. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base-salary severance, any earned but unpaid prior-year bonus, and up to 12 months of COBRA premium support, subject to specified conditions. He is also eligible for a restricted stock unit award valued at $1,400,000, vesting in four equal annual installments starting August 10, 2027, with the number of shares based on the grant-date closing price and capped at 280,000 shares. Hayden, subject to a separation agreement and release, will receive one year of base salary and up to one year of COBRA benefits.